Skip to main content
MMSI logo

MMSI · Merit Medical Systems Inc

Track MMSI — free
$85.93 +1.44 (+1.70%) At close · Nov 18
Market Cap
$5.15B
Shares
59.92M
Volume · Nov 18 494.17K Avg daily vol (3M) 659.01K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$85.93 Open$84.36 Day$83.89–86.37 52W close$60.31–94.20 Avg vol 30d721K Short int4.0M · 6.7% of shares · 5.1d Short vol63% Last earningsOct 29, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 29

Up next

Feb 23, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Third-quarter sales rise 8.4% to $416.2 million

Merit Medical Systems reported third-quarter sales of $416.2 million, up 8.4% from $384.2 million, and net income of $42.3 million, or $0.70 per share, versus $27.8 million, or $0.46 per share, a year earlier. Nine-month sales reached $1,217.0 million, up 8.5%, with therapeutic sales up 13.0%. The company also began commercial sales of OneMark products after acquiring View Point on April 1, 2026.

Revenue $416.24M ▲ 8.4% Net income $42.31M ▲ 52.4% Diluted EPS $0.70 ▲ 52.2%
Read from the MD&A section
5 source passages
For the three-month period ended September 30, 2026, we reported sales of $416.2 million, an increase of $32.1 million or 8.4% compared to sales for the three-month period ended September 30, 2025 of $384.2 million. Net income for the three-month period ended September 30, 2026 was $42.3 million, or $0.70 per share, compared to net income of $27.8 million, or $0.46 per share, for the three-month period ended September 30, 2025. For the nine-month period ended September 30, 2026, we reported sales of $1,217.0 million, an increase of $95.0 million or 8.5% compared to sales for the nine-month period ended September 30, 2025 of $1,122.0 million. Our therapeutic sales for the nine-month period ended September 30, 2026 were $404.8 million, up 13.0% when compared to sales in the corresponding period of 2025 of $358.3 million. On April 1, 2026, we completed the acquisition of View Point, which included the OneMark® Detection Imaging System and OneMark Tissue Markers used in the diagnosis and localization of breast and soft tissue tumors. Open the document at this passage
Oct 29
Current report 8-K
9% organic growth, raised guidance, Solo Pace acquisition

Merit Medical Systems, Inc. reported third-quarter revenue of $416.2 million, up 8.4%, with 9% organic constant-currency growth, and raised 2026 guidance. It also acquired Solo Pace on October 13, 2026 for approximately $45 million in cash.

Financial results, Regulation FD disclosure Read from the first part of this long document
6 source passages
Merit Medical Systems, Inc. (NASDAQ: MMSI) Reported revenue of $416.2 million, up 8.4% Constant currency revenue\* and constant currency revenue, organic\* up 8% and up 9%, respectively We have raised our 2026 revenue and non-GAAP earnings per share guidance Merit paid cash of approximately $45 million to acquire the outstanding equity interests of Solo Pace. on October 13, 2026 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.61B
Trailing 12 months
Net income (TTM)
$160.12M
Trailing 12 months
Revenue growth YoY
+8.4%
Year over year
Operating margin
13.5%
Trailing 12 months
P / E (TTM)
32.2
Trailing earnings · reciprocal yield 3.1%
FCF yield
4.0%
TTM · current market cap
Return on invested capital
8.3%
Trailing 12 months
Net cash
−$233.85M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.8%
Year over year · more shares
Price change (1Y)
+2.1%
Trailing year
Short interest
6.7%
Latest settlement · 5.1 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Jul 30, 2026
Q2 FY26

TL;DR. Q2 revenue beat expectations, organic growth was the strongest in three years, and full-year revenue and non-GAAP EPS guidance were raised. Headwinds include tariffs, lower operating margin excluding the tariff refund, a 2% renal therapies sales decline, and operating cash flow down 11% year-to-date.

Bullish
  • + Q2 total revenue beat expectations, with constant currency revenue above the high end of guidance.
  • + Full-year 2026 revenue and non-GAAP EPS guidance were raised.
  • + Organic growth was the strongest quarterly organic growth in three years.
  • + Total OEM sales grew 15% year-over-year in Q2, with improving OEM growth trends.
  • + Non-GAAP operating margin rose 142 basis points year-over-year to 22.6%.
  • + Non-GAAP EPS increased 18% year-over-year.
Bearish
  • − Tariffs are a 2026 headwind, with the non-GAAP EPS guidance assuming a tariff impact of about $0.21 per share.
  • − Operating margin excluding the tariff refund declined year-over-year.
  • − Renal therapies sales declined 2% in Q2, affected by a product recall.
  • − Operating cash flow fell 11% year-to-date.
  • − OEM sales are inherently lumpy and may move up and down from quarter to quarter.
  • − Management sees competitors active in Rhapsody, making the market a daily battle.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Neutral Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +11%
above
Price vs 50-day avg −2%
below
RSI (14) 45
neutral
MACD trend Negative
52-week position 76%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return −6%
trailing
6-month return +36%
trailing
YTD return −3%
this year
Relative strength +40%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $88 › 200d $77 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +70 funds added
Insider flow Distributing
Net -$678.4K over 90 days · 100% sells
Short interest Rising
6.67% of shares out · ▲ +5.3% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
424 holders — near 3-yr high, broad support
Squeeze score 61
elevated · 0–100
Fundamentals
Excellent
Revenue growth +12%
Y/Y
Gross margin 49%
expanding
EPS growth +5%
Y/Y
Free cash flow $215.7M
Valuation P/E 32.2
below peers
Balance sheet $287.6M
net debt
Quant / Vol
risk profile
Moderate
Volatility 31%
annualized · 1-yr
Max drawdown −35%
past year
ATR 3.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 7 of last 7
Latest guidance · from the 8-K filed Oct 29, 2026
2026
2026 Net Sales Guidance - % Change from Prior Year (GAAP) Raised 7.9% – 8.4%
Jul 30, 2026 7.6% – 8.4% changed to Oct 29, 2026 7.9% – 8.4%
2026 Net Sales Guidance - % Change from Prior Year (Constant Cur Raised 7% – 7.5%
Feb 24, 2026 5.4% – 6.7% changed to Oct 29, 2026 7% – 7.5%
Year Ending December 31, 2026
Total Revenue Maintained $1.64B – $1.64B
Jul 30, 2026 $1.63B – $1.64B changed to Oct 29, 2026 $1.64B – $1.64B
prior FY $1.52B midpoint +8.1% Y/Y
Non-GAAP Earnings Per Share(1) Raised $4.33 – $4.37
Feb 24, 2026 $4.01 – $4.15 changed to Oct 29, 2026 $4.33 – $4.37
Non-GAAP Earnings Per Share(1) 13% – 14%
Guided vs delivered · last 7 settled
Net Sales Year Ending December 31, 2025
guided $1.5B – $1.52B
$1.52B Beat +0.5%
Net Sales Year Ending December 31, 2024
guided $1.31B – $1.33B
$1.36B Beat +2.9%
Net Sales Year Ended December 31, 2023
guided $1.24B – $1.25B
$1.26B Beat +0.9%
Earnings Per Share Year Ended December 31, 2023
guided $1.52 – $1.58
$1.62 Beat +4.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+11% Bullish
Price vs 50-day avg
−2% Neutral
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
76% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $88 › 200d $77 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +70 funds added
Insider flow Distributing
Net -$678.4K over 90 days · 100% sells
Short interest Rising
6.67% of shares out · ▲ +5.3% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
424 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $60 Now $86 · 76% Range high $94
vs 200-day avg +11% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Aggregate amortization expense for developed technology and other intangible assets $21.2M Three Months Ended June 30, 2026 filing —
Capital Expenditures-Property and Equipment $17.3M Q2 2026 —
Constant Currency Revenue non-GAAP 789.8M Six Months Ended June 30, 2026 —
Constant Currency Revenue, Organic non-GAAP 774.45M Six Months Ended June 30, 2026 —
Domestic sales $252.1M three months ended June 30, 2026 filing —
Effective tax rate 24.4% Three Months Ended June 30, 2026 filing —
employees worldwide 7,500 as of release date —
Free cash flow non-GAAP $76.6M Six months ended June 30, 2026 —
Gross profit percentage 51.4% three months ended June 30, 2026 filing —
International sales $166.8M three months ended June 30, 2026 filing —
Non-GAAP Gross Margin non-GAAP 54.6% Six Months Ended June 30, 2026 —
Non-GAAP net income non-GAAP 127.94M Six Months Ended June 30, 2026 —
Non-GAAP Operating Income non-GAAP 169.89M Six Months Ended June 30, 2026 —
Non-GAAP Operating Margin non-GAAP 21.2% Six Months Ended June 30, 2026 +5.0%
Operating Cash Flow $69.3M Q2 2026 —
Selling, general and administrative expense as a percentage of sales 30.9% three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MMSI
Merit Medical Systems Inc
this stock
$5.15B -2.5% +11.8% 32.2 6.7%
ISRG
Intuitive Surgical Inc
$145.92B -25.7% +20.5% 51.0 2.0%
BDX
Becton Dickinson & Co
$58.86B — +8.2% 95.6 3.0%
MDLN
Medline Inc.
$51.51B -6.8% +11.5% — 2.9%
ALC
Alcon Inc
$36.15B -4.5% +10.5% — 3.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
424
% held
104.3%
Net QoQ
-82.0K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
410
View
Short & Settlement
Short Interest Rising
Shares short
4.0M
Days to cover
5.1d
Change
+203.0K sh
View
Short Volume
Short vol %
63%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
3.0K
Value
$281.6K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
49.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$678.4K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Sell
Member
Lisa McClain
Amount
$1.0K–$15.0K
Traded
Sep 25, 2025
View
Financials
Financials
Revenue (FY)
$1.5B
Net income (FY)
$128.5M
EPS diluted
$2.13
View
Buybacks
Authorized
shares 1.4M
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 29, 2026
This year
21

Merit Medical Systems reported third-quarter sales of $416.2 million, up 8.4% from $384.2 million, and net income of $42.3 million, or $0.70 per share, versus $27.8 million, or $0.46 per share, a year earlier. Nine-month sales reached $1,217.0 million, up 8.5%, with therapeutic sales up 13.0%. The company also began commercial sales of OneMark products after acquiring View Point on April 1, 2026.

View
Proposed Sales
Value
$1.4M
Shares
16.7K
Filed
Nov 16, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Oct 29, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
MMSI -2.4% -6.0% +36.3% -0.4% -2.5%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +1.5% -0.4% +39.7% +3.0% -9.6%

Capital returns

Buyback program · as of Apr 30, 2007
Authorized
shares 1.40M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 856982 CUSIP 589889104 13F (30d) 424 filings 385 filers Visit website Investor relations